



Decree of the Chairman of the Egyptian Drug Authority No. (481) of 2021

The Chairman of the Egyptian Drug Authority

Having reviewed:

- Law No. (127) of 1955 Regulating the Practice of the Pharmacy Profession;
- Law No. (182) of 1960 concerning the Combatting of Narcotic Drugs, the Regulation of Their Use and Trafficking Therein, and its amendments;
- Law No. (151) of 2019 concerning the Establishment of the Egyptian Drug Authority, and its Executive Regulations;
- The Single Convention on Narcotic Drugs of 1961;
- The Convention on Psychotropic Substances of 1971;
- Ministerial Decree No. (172) of 2011 concerning the Regulation of Handling of Psychotropic Medicinal Products;
- The Legal Opinion of the General Assembly of the Departments of Fatwa and Legislation of the State Council No. 634/1/58 issued in the session held on 7/8/2021;
- The recommendations of the Tripartite Committee formed from representatives of the Egyptian Drug Authority and the Ministries of Justice and Interior, convened on 17/10/2021;
- And based on the memorandum submitted by the Head of the Central Administration of Pharmaceutical Policies and Market Access at the Egyptian Drug Authority;

(Article One)

The following group, together with its derivatives, salts, isomers, esters, ethers, salts of isomers, esters thereof, and preparations thereof, wherever found, shall be added to Section Two of Schedule No. (1) annexed to Law No. (182) of 1960 concerning the Combatting of Narcotic Drugs, the Regulation of Their Use and Trafficking Therein:

Indole-Carboxamide

(Article Two)

This Decree shall be published in the Egyptian Gazette and shall enter into force as of the day following the date of its publication.

**Chairman of the Egyptian Drug Authority
Prof. Dr. Tamer Mohamed Essam**

Issued on: 19/10/2021